Differential expression of estrogen receptor-α on follicular dendritic cells from patients with grade 1-2 and grade 3 follicular lymphoma
Differential expression of estrogen receptor-α on follicular dendritic cells from patients with grade 1-2 and grade 3 follicular lymphoma
复制标题
DOI：
10.1002/hon.2577
复制
发表时间：
2019-04-01
影响因子：
3.3
通讯作者：
Yamakawa, Mitsunori
中科院分区：
文献类型：
--
作者：
Ohe, Rintaro;Meng, Hong-Xue;Yamakawa, Mitsunori
激素治疗已经用于雌激素受体α(ERα)阳性的乳腺癌患者。最近，一些研究报道了ERα在B细胞淋巴瘤肿瘤细胞上的表达。然而，目前仅有一例在滤泡树突状细胞(FDC)上表达ERα的报道，这些细胞在结构和功能上支持滤泡性淋巴瘤(FLS)的微环境。本研究的目的是检测非肿瘤性反应性淋巴组织中FDCs上ERα的表达频率，并比较抗雌激素治疗前后和FL 1~3级患者腋窝淋巴结中FDCs上ERα的表达频率。逆转录-聚合酶链式反应检测FL中ERα基因的表达。在扁桃体炎或反应性淋巴结炎患者的非肿瘤性生发中心(GC)，ERα在光区表达。ERα阳性细胞与GCs的宽度(r(S)=0.81，P<0.0 1)、CD2 1阳性细胞(r(S)=0.69，P<0.0 1)和CD2 3阳性细胞(r(S)=0.83，P<0.0 1)FDC网呈正相关。接受激素治疗的腋窝淋巴结中ERα阳性细胞较少，GC较小，CD21和CD23阳性的FDC网络较疏松(P<；0.01)。G1-2FL组的卵泡ERα阳性细胞较多，CD23(+)FDC网较G3FL组大(P<；0.01)。逆转录-聚合酶链式反应检测到G1-2FL和G3FL中ERαmRNA的表达。综上所述，这些结果提示抗雌激素激素治疗可以减少ERα阳性的FDCs的数量，并且在G1-2FL和G3FL中，雌激素-ERα相互作用对FDCs的反应可能不同。
Hormone therapy has been used for patients with estrogen receptor alpha (ER alpha)-positive breast cancers. Recently, some studies reported the expression of ER alpha on neoplastic cells from B-cell lymphomas. However, there has been only one report of ER alpha expression on the follicular dendritic cells (FDCs) that structurally and functionally support the microenvironment of follicular lymphomas (FLs). The objective of this study was to investigate the frequency of ER alpha expression on FDCs in nonneoplastic reactive lymphoid tissues and to compare the frequency of ER alpha expression on FDCs in the axillary lymph nodes between patients with and without antiestrogen therapy and among patients with grades 1-3 of FL. Reverse transcription-polymerase chain reaction was performed to detect ER alpha mRNA in FL. In nonneoplastic germinal centers (GCs) from patients with tonsillitis or reactive lymphadenitis, ER alpha was expressed in the light zone. ER alpha-positive cells strongly correlated with the width of GCs (r(s) = 0.81, P < 0.01) and the CD21-positive (r(s) = 0.69, P < 0.01) and CD23-positive (r(s) = 0.83, P < 0.01) FDC meshwork. The axillary lymph nodes had fewer ER alpha-positive cells, smaller GCs, and a looser CD21- and CD23-positive FDC meshwork with hormone therapy than without hormone therapy (P < 0.01). Neoplastic follicles of G1-2 FL had more ER alpha-positive cells and a larger CD23(+) FDC meshwork than those of G3 FL (P < 0.01). ER alpha mRNA was detected in both G1-2 FL and G3 FL by reverse transcription-polymerase chain reaction. In conclusion, these results suggested that antiestrogen hormone therapy may decrease the number of ER alpha-positive FDCs and that the responses mediated by the estrogen-ER alpha interaction on FDCs may differ between G1-2 FL and G3 FL.